Last reviewed: June 20, 2026 Last updated: June 20, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
With decades of experience treating complex cases and a multidisciplinary team of providers, PMC has the clinical infrastructure to use peptide therapy where it will make the most difference for your specific situation
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway
Cognitive behavioral therapy remains the first-line treatment with the strongest evidence base
Health researchers acknowledge this problem and are working toward determining more accurate cutoffs for deficient, suboptimal, adequate, and excess micronutrient status
La mayora de los pacientes notan cambios en el apetito en las primeras semanas y una prdida de peso visible en 4-6 semanas